Lexaria Bioscience Corp Total Assets
Lexaria Bioscience Corp total assets. Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) holds total assets worth $4.78 Million USD as of May 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LEXX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Lexaria Bioscience Corp (2005–2025)
Total assets of Lexaria Bioscience Corp from 2005 to 2025. This chart illustrates how Lexaria Bioscience Corp's total assets have evolved over time, based on quarterly financial data. See Lexaria Bioscience Corp stock price for real-time trading data and today's change.
Lexaria Bioscience Corp - Asset Composition Analysis
Lexaria Bioscience Corp Total Assets Breakdown (August 2025)
Lexaria Bioscience Corp total assets breakdown as of August 2025. Lexaria Bioscience Corp's total assets of $4.78 Million consist of 83.1% current assets and 16.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.2% |
| Accounts Receivable | $174.00K | 4.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $307.82K | 7.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Lexaria Bioscience Corp to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lexaria Bioscience Corp's current assets represent 83.1% of total assets in 2025, an increase from 80.1% in 2005.
- Cash Position: Cash and equivalents constituted 43.2% of total assets in 2025, down from 78.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 7.4% of total assets.
Lexaria Bioscience Corp Competitors by Total Assets
Key competitors of Lexaria Bioscience Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Lexaria Bioscience Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.60 | 3.90 | 81.18 |
| Quick Ratio | 10.60 | 3.90 | 80.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.68 Million | $4.32 Million | $12.29 Million |
Lexaria Bioscience Corp - Advanced Valuation Insights
This section examines the relationship between Lexaria Bioscience Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.80 |
| Latest Market Cap to Assets Ratio | 2.00 |
| Asset Growth Rate (YoY) | -52.9% |
| Total Assets | $4.18 Million |
| Market Capitalization | $8.36 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lexaria Bioscience Corp's assets above their book value (2.00x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Lexaria Bioscience Corp's assets decreased by 52.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual total assets of Lexaria Bioscience Corp from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $4.18 Million | -52.92% |
| 2024-08-31 | $8.87 Million | +187.54% |
| 2023-08-31 | $3.08 Million | -60.63% |
| 2022-08-31 | $7.83 Million | -40.95% |
| 2021-08-31 | $13.27 Million | +369.08% |
| 2020-08-31 | $2.83 Million | +5.72% |
| 2019-08-31 | $2.68 Million | +10.01% |
| 2018-08-31 | $2.43 Million | -14.98% |
| 2017-08-31 | $2.86 Million | +404.76% |
| 2016-08-31 | $566.64K | -20.38% |
| 2015-08-31 | $711.72K | -80.08% |
| 2014-08-31 | $3.57 Million | 0.00% |
| 2013-08-31 | $3.57 Million | -2.98% |
| 2012-08-31 | $3.68 Million | -15.13% |
| 2011-08-31 | $4.34 Million | +12.28% |
| 2010-08-31 | $3.86 Million | +13.06% |
| 2009-08-31 | $3.42 Million | +5.18% |
| 2008-08-31 | $3.25 Million | -14.38% |
| 2007-08-31 | $3.80 Million | +39.59% |
| 2006-08-31 | $2.72 Million | +147.09% |
| 2005-08-31 | $1.10 Million | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more